Biomarker Correlates of Clinical Outcomes from a Global phase 1b Study of JNJ-90014496, CD20/CD19 Bi-Specific Chimeric Antigen Receptor (CAR) T-cell Therapy for Patients with Large B-cell Lymphoma (LBCL)
Mahipal Suraneni(Johnson & Johnson (United States)), Vicki Plaks(Johnson & Johnson (United States)), Luke Mountjoy(Colorado Blood Cancer Institute), Jianmei Wu(Johnson & Johnson (United States)), Leen Slaets(European Organisation for Research and Treatment of Cancer), Daksh Thaper(Johnson & Johnson (United States)), Arnob Banerjee(Johnson & Johnson (United States)), Jacqueline Bussolari(Johnson & Johnson (United States)), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Donne Bennett Caces(Johnson & Johnson (United States)), Shajo Kunnath-Velayudhan(Johnson & Johnson (United States)), Dianna Wu(Memorial Sloan Kettering Cancer Center), Matthew Ku(The University of Melbourne), Krish Patel, Da Yin(Johnson & Johnson (United States)), Martin Hutchings(University of Copenhagen), Alfredo Perales-Puchalt(Johnson & Johnson (United States)), Melissa Beelen(Janssen (United States)), Julie Larsen(Johnson & Johnson (United States)), Jacob Haaber(Odense University Hospital)
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k